Assessment of some clinical pathogenetic interactions in patients with atrial fi brillation in combination with the arterial hypertension and extracardiac pathology
https://doi.org/10.31549/2542-1174-2019-2-29-37
Abstract
A prospective cohort study included 173 men 45–65 years with arterial hypertension (AH) and atrial fi brillation (AF). The 1st group consisted 53 patients with abdominal obesity (AO) and with diabetes mellitus of type 2; the 2nd group consisted 64 patients with AO without diabetes mellitus; the 3rd group was the comparison one it included 56 patients with AH and AF without accompanied pathology. The studied groups differed on age: average of patients of the 1st and 2nd group was reliably senior, than in patients of the comparison group. During the comparison of biochemical parameters it was found that patients of the 1st and 2nd group had a signifi cant increase in potassium, creatinine, urea compared of the comparison group higher. The fi brosis marker galectin-3 was higher in patients of the 1st group then in patients of the control group. In patients of the 1st and 2nd group there was a signifi cant decrease of the index of mass a myocardium of the left ventricular (IMMLV) compared to patients of the comparison group. The decrease of the IMMLV with concomitant comorbid pathology may be associated with metabolic processes that can slow compensatory muscular hypertrophy of the myocardium. Thus, patients with atrial fi brillation on the background of arterial hypertension, abdominal obesity and diabetes mellitus needed early diagnostics and correction of both AH and extracardial comorbid diseases in order to prevent early and rapidly progressive myocardial lesions.
About the Authors
D. A. Yakhontov
Novosibirsk State Medical University
Russian Federation
Russian Federation
Yakhontov Davyd Aleksandrovich — Dr. Sci. (Med.), Professor of the Department of Pharmacology, Clinical Pharmacology and Evidentiary Medicine
Novosibirsk
L. D. Khidirova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Khidirova Lyudmila Daudovna — Cand. Sci. (Med.), Associate Professor of the Department of Pharmacology, Clinical Pharmacology and Evidentiary Medicine
52, Krasny Prospect, Novosibirsk, 630091
S. A. Zenin
Novosibirsk Regional Clinical Cardiologic Dispensary
Russian Federation
Russian Federation
Zenin Sergey Anatolyevich — Dr. Sci. (Med.), Head of the Department of Arrhythmology
Novosibirsk
References
1. Yakhontov D.A., Zenin S.A., Khidirova L.D., Kireeva O.V. (2018). Atrial fibrillation and arterial hypertension associated with non-coronarogenic origin diseases. J. Sib. Med. Sci., 1, 4–10.
2. Grebenkina I.A., Popova A.A., Mayanskaya S.D. et al. (2018). Condition of a wall of a carotid artery in young faces with the anamnesis burdened on arterial hypertension. J. Sib. Med. Sci., 4, 42– 53.
3. Drapkina O.M., Kostyukevich M.V. (2010). Arterial hypertension: from atrial fi brillation and a stroke to a metabolic syndrome. Reference Book of the Policlinic Doctor, 8, 37–39. In Russ.
4. Drapkina O.M., Yemelyanov A.V. (2013). Fibrosis and atrial fi brillation — mechanisms and treatment. Arterial Hypertension, 19, 6, 487–494. In Russ.
5. Oganov R.G. (2002). Prevention of cardiovascular diseases: possibilities of practical health care. Cardiovascular Therapy and Prevention, 1, 15–16. In Russ.
6. Ahmad T., Fiuzat M., Neely B. et al. (2014). Biomarkers of myocardial stress and fi brosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fai., 2, 3, 260–268. doi: 10.1016/j.jchf.2013.12.004.
7. Ho J.E., Yin X., Levy D. et al. (2014). Galectin 3 and incident atrial fi brillation in the community. Am. Heart J., 167, 5, 729–734.
8. Belluzzi F., Sernesi L., Preti P. et al. (2009). Prevention of recurrence lone atrial fi brillation by the angiotensinII converting enzyme inhibitor ramipril in normotensive patients. JACC, 53, 24–29. doi: 10.1016/j.jacc.2008.08.071.
9. Gurses K.M., Yalcin M.U., Kocyigit D. et al. (2015). Effects of persistent atrial fi brillation on serum galectin3 levels. Am. J. Cardiol., 115, 5, 647–651.
10. Ionin V.A., Listopad O.V., Nifontov S.E. et al. (2014). Galektin 3 in patients with metabolic syndrome and atrial fi brillation. Arterial Hypertension, 20, 5, 462– 469.
11. Boss Ch.J., Lip G.Y.H. (2005). Targeting the reninangiotensinaldosterone system in atrial fi brillation: from pathology to clinical trials. J. Hum. Hypertens., 19, 855–859.
12. Cheruku K.K., Ghani A., Ahmad F. et al. (2004). Efficacy of nonsteroidal anti-inflammatory medications for prevention of atrial fibrillation following coronary artery bypass graft surgery. Prev. Cardiol., 7, 1, 13–18.
13. Sideris A.N., Letsas K. (2006). Inflammation and atrial fibrillation. Hospital Chronicles. Suppl., 128– 134.
14. Weber M., Hamm C. (2006). Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart, 92, 6, 843–849. doi: 10.1136/hrt.2005.071233.
15. Shlyakhto E.V., Nedogoda S.V., Konradi A.O. et al. (2016). The concept of novel national clinical guidelines on obesity. Russ. J. Cardiol., 21, 4, 7–13. doi. org/10.15829/1560-4071-2016-4-7-13. In Russ.
Review
For citations:
Yakhontov D.A., Khidirova L.D., Zenin S.A. Assessment of some clinical pathogenetic interactions in patients with atrial fi brillation in combination with the arterial hypertension and extracardiac pathology. Journal of Siberian Medical Sciences. 2019;(2):29-37. https://doi.org/10.31549/2542-1174-2019-2-29-37
Views:
230
Email this article 